Laura W. Goff, MD

Articles

The Evolving Treatment Landscape of Biliary Tract Cancers

July 4th 2023

Closing out their discussion on biliary tract cancers, Milind Javle, MD, and Laura Goff, MD, highlight current treatment guidelines and unmet needs as the landscape continues to evolve.

Other Clinical Trials With Chemoimmunotherapy in Biliary Tract Cancers

July 4th 2023

Expert perspectives on the KEYNOTE-966 and IMbrave151 clinical trials and novel chemoimmunotherapy combination strategies in biliary tract cancers.

Chemoimmunotherapy in Biliary Tract Cancers: Data From TOPAZ-1

June 27th 2023

Centering discussion on data from TOPAZ-1, Milind Javle, MD, and Laura Goff, MD, reflect on the value of chemoimmunotherapy combinations in biliary tract cancer management.

Biliary Tract Cancers: Standard of Care Treatment Strategies

June 27th 2023

Drs Javle and Goff review standard of care treatment strategies for the management of biliary tract cancer and discuss recent NCCN guideline updates for the combination of durvalumab + cisplatin + gemcitabine.

What is the Role of Biomarker Testing in Biliary Tract Cancers?

June 20th 2023

Shared insight on the role of molecular testing in the diagnosis of biliary tract cancers and how it may inform the selection of optimal therapy.

Overview of Biliary Tract Cancers and Diagnosis

June 20th 2023

Expert oncologists Milind Javle, MD, and Laura Goff, MD, reflect on the subsets of biliary tract cancers and consider best practices in making an accurate diagnosis.

Dr Goff on the Investigation of Adjuvant Atezolizumab Plus Bevacizumab in HCC

May 16th 2023

Laura Goff, MD, discusses the investigation of adjuvant atezolizumab plus bevacizumab in hepatocellular carcinoma.

Dr Goff on Key Takeaways from the SWOG 1815 Trial in Biliary Tract Cancers

May 12th 2023

Laura Goff, MD, discusses the key takeaways from results of the phase 3 SWOG 1815 trial in newly diagnosed patients with advanced biliary tract cancers.

Dr. Goff on Leveraging Clinical Trial Information to Inform Treatment Decisions in HCC

October 18th 2022

Laura Goff, MD, discusses how to consider clinical trial information to inform treatment decisions in patients with hepatocellular carcinoma.

Dr. Goff on the Need to Identify Novel Targets in HCC

October 29th 2020

Laura Goff, MD, discusses the need to identify novel targets in hepatocellular carcinoma.

Adjuvant Therapy for Biliary Tract Cancers Advance

December 28th 2017

Biliary tract cancers are rare but deadly diseases, subdivided into intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, and gallbladder carcinoma.